Literature DB >> 7711419

Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide.

J X de Vries1, A Voss, A Ittensohn, I Walter-Sack, W Löffler, R Landthaler, N Zöllner.   

Abstract

The kinetics of allopurinol and hydrochlorothiazide were investigated in seven healthy male subjects during prolonged coadministration of two drugs. Subjects were maintained on an isoenergetic, purine-free formula diet with RNA supplementation for 24 days. Allopurinol (300 mg) was given orally on days 1-24. Hydrochlorothiazide (50 mg daily) was added to days 11-21. On day 43 a single oral dose of 50 mg hydrochlorothiazide was administered. Plasma concentration-time profiles of allopurinol and its main metabolite oxipurinol were obtained on days 1, 10, and 21; hydrochlorothiazide profiles were assessed on days 21 and 43. In addition, 24-h plasma concentrations of oxipurinol were measured repetitively, and 24 h urine samples were collected for the determination of allopurinol, oxipurinol, and hydrochlorothiazide. For oxipurinol, mean Cmax was not altered on hydrochlorothiazide treatment (13.8 +/- 1.4 micrograms/ml and 14.7 +/- 2.6 micrograms/ml, respectively); mean AUC0-24 was 259 and 290 micrograms h-1 ml-1, respectively. The small difference in AUC0-24 values does not explain the increase in plasma uric acid concentration during hydrochlorothiazide treatment, nor do the variations in allopurinol and hydrochlorothiazide kinetics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711419     DOI: 10.1007/bf00577759

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  19 in total

1.  Clinical significance of hyperuricemia in routinely screened hospitalized men.

Authors:  H E Paulus; A Coutts; J J Calabro; J R Klinenberg
Journal:  JAMA       Date:  1970-01-12       Impact factor: 56.272

Review 2.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

3.  Acute adverse reactions attributed to allopurinol in hospitalised patients.

Authors:  G T McInnes; D H Lawson; H Jick
Journal:  Ann Rheum Dis       Date:  1981-06       Impact factor: 19.103

4.  [Prevention of urinary calculi with thiazides and allopurinol. A long-term study].

Authors:  P May; H Pilorz; C Duhme; H Pöpperl; J Braun
Journal:  Urologe A       Date:  1984-03       Impact factor: 0.639

5.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

6.  Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

Authors:  B Breithaupt; M Tittel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Simple determination of hydrochlorothiazide in human plasma and urine by high performance liquid chromatography.

Authors:  J X de Vries; A Voss
Journal:  Biomed Chromatogr       Date:  1993 Jan-Feb       Impact factor: 1.902

8.  Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol.

Authors:  G Maschio; N Tessitore; A D'Angelo; A Fabris; F Pagano; A Tasca; G Graziani; A Aroldi; M Surian; G Colussi; A Mandressi; A Trinchieri; F Rocco; C Ponticelli; L Minetti
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

9.  Simultaneous determination of allopurinol and oxipurinol in human plasma and urine by high-performance liquid chromatography.

Authors:  J X de Vries; A Voss; C Kutschker; S Reiter
Journal:  Arzneimittelforschung       Date:  1993-10

10.  Evaluation of a thiazide-allopurinol drug interaction.

Authors:  K R Hande
Journal:  Am J Med Sci       Date:  1986-10       Impact factor: 2.378

View more
  3 in total

1.  Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.

Authors:  Daniel Y Ng; Sophie L Stocker; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Eur J Clin Pharmacol       Date:  2010-12-23       Impact factor: 2.953

Review 2.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Risk factors for cutaneous reactions to allopurinol in Kinh Vietnamese: results from a case-control study.

Authors:  Minh Duc Do; Thao Phuong Mai; Anh Duy Do; Quang Dinh Nguyen; Nghia Hieu Le; Linh Gia Hoang Le; Vu Anh Hoang; Anh Ngoc Le; Hung Quoc Le; Pascal Richette; Matthieu Resche-Rigon; Thomas Bardin
Journal:  Arthritis Res Ther       Date:  2020-08-03       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.